Banff Borderline Changes Suspicious for Acute T Cell-Mediated Rejection: Where Do We Stand?

被引:45
|
作者
Becker, J. U. [1 ]
Chang, A. [2 ]
Nickeleit, V. [3 ]
Randhawa, P. [4 ]
Roufosse, C. [5 ]
机构
[1] Univ Cologne, Inst Pathol, Cologne, Germany
[2] Univ Chicago Med, Chicago, IL USA
[3] Univ N Carolina, Div Nephropathol, Dept Pathol, Chapel Hill, NC USA
[4] Univ Pittsburgh, Dept Pathol, UPMC Montefiore, Thomas E Starzl Txn Inst, Pittsburgh, PA USA
[5] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Cellular Pathol, London, England
关键词
clinical research; practice; pathology; histopathology; kidney transplantation; nephrology; classification systems: Banff classification; guidelines; rejection: T cell mediated (TCMR); RENAL-ALLOGRAFT REJECTION; PROTOCOL BIOPSIES; TRANSPLANT RECIPIENTS; SUBCLINICAL REJECTION; WORKING CLASSIFICATION; REPRODUCIBILITY; NEPHROPATHY; CRITERIA; EXPRESSION; DIAGNOSIS;
D O I
10.1111/ajt.13784
中图分类号
R61 [外科手术学];
学科分类号
摘要
The definition of Banff Borderline became ambiguous when the Banff 2005 consensus modified the lower threshold from i1t1 (10-25% interstitial inflammation with mild tubulitis) to i0t1 (0-10% interstitial inflammation with mild tubulitis). We conducted a worldwide survey among members of the Renal Pathology Society about their approach to this diagnostic category. A web-based survey was sent out to all 503 current members (153 respondents). A database search yielded which threshold for Banff i was applied in the most influential manuscripts about Borderline. Among the 139 nephropathologists using the Borderline category, 67% use the Banff 1997 definition, requiring Banff i1. Thirty-seven percent admitted to sometimes exaggerating Banff i in the presence of tubulitis, to reach a diagnosis of Borderline. Forty-eight percent were dissatisfied with the definition of Borderline. The majority of the most influential manuscripts used the 1997 definition, contrary to the current one. There is considerable dissatisfaction with Borderline, and practice in Banff i thresholds is variable. Until additional studies inform a revision, we suggest leaving it to each pathologist's discretion whether to use i0 or i1 as the minimal threshold. In order to avoid future ambiguity, a web-based synopsis of all scattered current Banff definitions and rules should be created. The authors investigate the approach to the diagnosis of Banff borderline acute T cell-mediated rejection and find that most nephropathologists do not adhere to current Banff guidelines, but still use the old minimal threshold for tubulointerstitial infiltrates.
引用
收藏
页码:2654 / 2660
页数:7
相关论文
共 50 条
  • [1] Long Term Graft Outcome after Subclinical Banff Borderline Changes Suspicious for Acute T Cell-Mediated Rejection
    Han, A.
    Ko, H.
    Chung, C.
    Kim, H.
    Min, S.
    Ha, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 401 - 401
  • [2] Borderline (suspicious) for T-cell-mediated rejection, the Banff classification's Achilles' heel
    van Baardwijk, Myrthe
    Wagenmakers, Anne
    van den Bosch, Thierry P. P.
    Hesselink, Dennis A.
    Loupy, Alexandre
    Kramann, Rafael
    van Huyen, Jean-Paul Duong
    Rabant, Marion
    Clahsen-van Groningen, Marian C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [3] IL-6 PRODUCTION BY MONOCYTES IS ASSOCIATED WITH GRAFT FUNCTION DECLINE IN PATIENTS WITH BORDERLINE CHANGES SUSPICIOUS FOR ACUTE T CELL-MEDIATED REJECTION
    Desy, O.
    Beland, S.
    Vallin, P.
    Riopel, J.
    Latulippe, E.
    Najafian, N.
    Chandraker, A.
    Agharazii, M.
    Houde, I.
    Batal, I.
    De Serres, S. A.
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 14 - 14
  • [4] Do we need to treat chronic active T cell-mediated rejection?
    Mengel, Michael
    Lubetzky, Michelle
    [J]. KIDNEY INTERNATIONAL, 2021, 100 (02) : 275 - 277
  • [5] The clinical and pathological significance of borderline T cell-mediated rejection
    Nankivell, Brian J.
    Agrawal, Nidhi
    Sharma, Ankit
    Taverniti, Anne
    P'Ng, Chow H.
    Shingde, Meena
    Wong, Germaine
    Chapman, Jeremy R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (05) : 1452 - 1463
  • [6] Impact of the Current Versus the Previous Diagnostic Threshold on the Outcome of Patients With Borderline Changes Suspicious for T Cell-mediated Rejection Diagnosed on Indication Biopsies
    McRae, Michael
    Bouchard-Boivin, Francois
    Beland, Stephanie
    Noel, Real
    Cote, Isabelle
    Lapointe, Isabelle
    Lesage, Julie
    Latulippe, Eva
    Riopel, Julie
    Santoriello, Dominick
    Husain, Syed A.
    Desy, Olivier
    Houde, Isabelle
    Batal, Ibrahim
    De Serres, Sacha A.
    [J]. TRANSPLANTATION, 2018, 102 (12) : 2120 - 2125
  • [7] Antibody-mediated rejection of the cardiac allograft: where do we stand in 2012?
    Berry, Gerald J.
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2012, 17 (03) : 303 - 308
  • [8] Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection
    Wiebe, Chris
    Rush, David N.
    Gibson, Ian W.
    Pochinco, Denise
    Birk, Patricia E.
    Goldberg, Aviva
    Blydt-Hansen, Tom
    Karpinski, Martin
    Shaw, Jamie
    Ho, Julie
    Nickerson, Peter W.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (09) : 2499 - 2508
  • [9] Pancreas transplantation, antibodies and rejection: where do we stand?
    de Kort, Hanneke
    Roufosse, Candice
    Bajema, Ingeborg M.
    Drachenberg, Cinthia B.
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2013, 18 (03) : 337 - 344
  • [10] Targeting T-cell memory: where do we stand?
    Valujskikh, Anna
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2008, 13 (04) : 344 - 349